MedPath

TORRENT PHARMACEUTICALS

🇮🇳India
Ownership
-
Established
1959-01-01
Employees
-
Market Cap
$13.7B
Website
http://www.torrentpharma.com/

Clinical Trials

104

Active:0
Completed:86

Trial Phases

5 Phases

Phase 1:72
Phase 2:5
Phase 3:11
+2 more phases

Drug Approvals

126

FDA:57
CANADA:25
PHILIPPINES:19

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (98 trials with phase data)• Click on a phase to view related trials

Phase 1
72 (73.5%)
Phase 3
11 (11.2%)
Not Applicable
6 (6.1%)
Phase 2
5 (5.1%)
Phase 4
3 (3.1%)
phase_1_2
1 (1.0%)

Efficacy and Safety of TRC041266 in Patients With Heart Failure, LVEF ≥40%, Diastolic Dysfunction and Type 2 Diabetes Mellitus

Phase 3
Withdrawn
Conditions
Chronic Stable Heart Failure
Interventions
Drug: Placebo
First Posted Date
2020-08-11
Last Posted Date
2022-12-27
Lead Sponsor
Torrent Pharmaceuticals Limited
Registration Number
NCT04507347

Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Phase 3
Completed
Conditions
Acne Vulgaris
Interventions
First Posted Date
2019-07-11
Last Posted Date
2020-04-02
Lead Sponsor
Torrent Pharmaceuticals Limited
Target Recruit Count
1150
Registration Number
NCT04015375
Locations
🇺🇸

Unison Center for Clinical Trials, Sherman Oaks, California, United States

🇺🇸

MOORE Clinical Research, Inc., Brandon, Florida, United States

🇺🇸

FXM Clinical Research Miami, Miami, Florida, United States

and more 10 locations

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Forest Pharmaceuticals Inc's Bystolic Tablets
First Posted Date
2018-05-07
Last Posted Date
2018-05-07
Lead Sponsor
Torrent Pharmaceuticals Limited
Target Recruit Count
22
Registration Number
NCT03517020

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Forest Pharmaceuticals Inc.'s Bystolic Tablets
First Posted Date
2018-05-07
Last Posted Date
2018-05-07
Lead Sponsor
Torrent Pharmaceuticals Limited
Target Recruit Count
30
Registration Number
NCT03517033

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Daiichi Sankyo Inc's Benicar Tablets 40 mg
First Posted Date
2017-10-24
Last Posted Date
2017-10-24
Lead Sponsor
Torrent Pharmaceuticals Limited
Target Recruit Count
34
Registration Number
NCT03319706
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 15
  • Next

News

Oops! Someting went wrong.
An unexpected error occurred, sorry about that. We've been notified and will get started on a fix.
An error occurred while fetching news

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.